New preclinical data supports immuno-oncology approach

• New preclinical data supports Sofra technology's potential in immuno-oncology
• Significant immune activation observed with TLR8-amplifying oligonucleotide
• Findings advance Noxopharm's oncology program towards in vivo proof-of-concept studies

Noxopharm Limited, an Australian clinical-stage biotechnology company, has generated new preclinical data demonstrating that its Sofra technology can activate immune cells in response to dying cancer cells. The study, conducted with Hudson Institute of Medical Research, found that Noxopharm's TLR8-amplifying oligonucleotide enabled immune cells to respond to dying cancer cells, providing further support for the technology's potential in immuno-oncology. The results build on earlier research showing the technology can help expose otherwise 'hidden' RNA to the immune system. The latest study extends this work to whole cancer cell debris, more closely reflecting what occurs when cancer cells die. This provides an important additional step in validating the Sofra approach for oncology and supports further development towards in vivo proof-of-concept studies.